Clinical leaders from the University of Kentucky Markey Cancer Center College of Medicine and College of Pharmacy are now embarking on a novel path to investigate COVID-19 therapies. In a first in the United States, a major academic medical center has taken on Ivermectin as an experimental therapy targeting SARS-CoV-2, the virus that causes COVID-19—along with azithromycin and camostat mesylate. These drugs all could potentially inhibit replication of SARS-CoV-2. All three of these therapies will be tested alone or in combination with the antimalarial drug hydroxychloroquine. In a “pick-the-winner” trial, innovation and pragmatic experimentation meet clinical research collaboration in the Bluegrass State.
TrialSite News has received hundreds of thousands of visits to our published material covering Ivermectin. From our first exposure of the University of Monash findings that the anti-parasitic medication can zap SARS-CoV-2 in a lab cell culture and the MedinCell research in France to clinical trials in Egypt and Iraq and of course the physician in Broward County using Ivermectin with dozens of patients—and apparently securi...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).